Home » Delta hepatitis and HIV co-infection: new guidelines and emerging treatments

Delta hepatitis and HIV co-infection: new guidelines and emerging treatments

by admin
Delta hepatitis and HIV co-infection: new guidelines and emerging treatments

L’Delta hepatitisa severe form of viral hepatitis, poses a significant threat to patients with Hivaccelerating the progression towards liver cirrhosis and increasing the risk of liver-related mortality. During the CROI Congress 2024 in Denver have been discussed new guidelines and emerging treatments to address this medical challenge.

Epidemic detection

Delta hepatitis has a significant impact on people with HIV, with prevalence varying between European cohorts. Data from studies in the Netherlands, France, Italy and the United States highlight a high incidence of co-infection, especially among intravenous drug users and patients co-infected with hepatitis C.

Advertisements

Importance of early screening

Current guidelines recommend regular screening to early detect hepatitis delta co-infection in HBs antigen-positive HIV patients. However, the retrospective analysis highlights disparities in testing, with a low screening rate among patients with hepatitis C infection and HIV co-infection, increasing the risk of undiagnosed cases.

Emerging treatments

New European guidelines suggest the combined use of bulevirtide and TDF to block the entry of viruses into the hepatocyte. This promising therapeutic approach is emerging as a potential solution to combat Delta hepatitis. Recent studies have shown a good viral and combined response to treatment, with further data expected in the short term.

Conclusions and future prospects

The main objective in the management of hepatitis delta and HIV co-infection should be to increase awareness, screening and access to treatment. It is crucial to closely monitor patients with advanced fibrosis or cirrhosis and develop easier-to-administer drugs to improve patient compliance and outcome.

Conclusions

In conclusion, addressing hepatitis delta and HIV co-infection requires an integrated approach that includes regular screening, access to effective treatments, and careful surveillance of at-risk patients. New guidelines and emerging treatments offer hope for improving the quality of life and survival of patients with this serious condition.

See also  Symptoms of Alzheimer's disease: a conference in Foggia

Nurse Times editorial team

Related articles:

Find out how to earn money by publishing your thesis on NurseTimes

The NEXT project is renewed and becomes NEXT 2.0: we publish the questionnaires and your theses

Upload your thesis:tesi.nursetimes.org

Upload your questionnaire:

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy